Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAmerican University of Beirut Medical Center
About this trial
The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.
Eligibility criteria
Qualifiers
Subject is ≥ 18 years of age.
Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.
Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria)
Disqualifiers
Subject with isolated anterior uveitis.
Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes simplex virus (HSV).
Subject with serpiginous choroidopathy.
Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.
Trial design
Treatments tested in this trial
- Adalimumab
Treatment groups
32 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov